Sequential chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type

Jieun Lee, Chul Yong Kim, Young Je Park, Nam Kwon Lee

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: The purpose of this report is to summarize our clinical experience of patients with stage I/II extranodal natural killer (NK)/T-cell lymphoma, nasal type, treated using sequential chemotherapy followed by radiotherapy (SCRT) or concurrent chemoradiotherapy (CCRT). Methods: Forty-three patients with stage I/II extranodal NK/T-cell lymphoma, nasal type, who received SCRT (16 patients) or CCRT (27 patients) were included in the present analysis. Results: The median follow-up time was 39 months (range, 4-171 months) for all patients, 77 months (range, 4-171 months) for the SCRT group, and 31 months (range, 6-132 months) for the CCRT group. There were no statistically significant differences between the SCRT and CCRT groups with regard to the 3-year progression-free survival (PFS) (56% vs. 41%, P=0.823) and 3-year overall survival (OS) (75% vs. 59%, P=0.670). Univariate analysis revealed that patients with tumors confined to the nasal cavity and patients achieved complete remission had better PFS and OS rates, regardless of the treatment sequence. Multivariate analysis revealed that patients with tumors confined to the nasal cavity and patients aged ≤60 years had better OS rates. Conclusion: The effect of SCRT and CCRT are similar in terms of survival outcomes of patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Our results show that tumors confined to the nasal cavity and an age ≤60 years were associated with a better prognosis.

Original languageEnglish
Pages (from-to)274-281
Number of pages8
JournalBlood Research
Volume48
Issue number4
DOIs
Publication statusPublished - 2013 Dec 1

Fingerprint

Natural Killer T-Cells
T-Cell Lymphoma
Chemoradiotherapy
Nose
Radiotherapy
Drug Therapy
Nasal Cavity
Disease-Free Survival
Survival Rate
Neoplasms
Survival
Multivariate Analysis

Keywords

  • Chemoradiotherapy
  • Extranodal NK/T-cell lymphoma
  • Nasal type
  • Treatment outcome

ASJC Scopus subject areas

  • Hematology

Cite this

Sequential chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type. / Lee, Jieun; Kim, Chul Yong; Park, Young Je; Lee, Nam Kwon.

In: Blood Research, Vol. 48, No. 4, 01.12.2013, p. 274-281.

Research output: Contribution to journalArticle

@article{4b4b619d2034468a99217fb5e63b7c73,
title = "Sequential chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type",
abstract = "Background: The purpose of this report is to summarize our clinical experience of patients with stage I/II extranodal natural killer (NK)/T-cell lymphoma, nasal type, treated using sequential chemotherapy followed by radiotherapy (SCRT) or concurrent chemoradiotherapy (CCRT). Methods: Forty-three patients with stage I/II extranodal NK/T-cell lymphoma, nasal type, who received SCRT (16 patients) or CCRT (27 patients) were included in the present analysis. Results: The median follow-up time was 39 months (range, 4-171 months) for all patients, 77 months (range, 4-171 months) for the SCRT group, and 31 months (range, 6-132 months) for the CCRT group. There were no statistically significant differences between the SCRT and CCRT groups with regard to the 3-year progression-free survival (PFS) (56{\%} vs. 41{\%}, P=0.823) and 3-year overall survival (OS) (75{\%} vs. 59{\%}, P=0.670). Univariate analysis revealed that patients with tumors confined to the nasal cavity and patients achieved complete remission had better PFS and OS rates, regardless of the treatment sequence. Multivariate analysis revealed that patients with tumors confined to the nasal cavity and patients aged ≤60 years had better OS rates. Conclusion: The effect of SCRT and CCRT are similar in terms of survival outcomes of patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Our results show that tumors confined to the nasal cavity and an age ≤60 years were associated with a better prognosis.",
keywords = "Chemoradiotherapy, Extranodal NK/T-cell lymphoma, Nasal type, Treatment outcome",
author = "Jieun Lee and Kim, {Chul Yong} and Park, {Young Je} and Lee, {Nam Kwon}",
year = "2013",
month = "12",
day = "1",
doi = "10.5045/br.2013.48.4.274",
language = "English",
volume = "48",
pages = "274--281",
journal = "Blood Research",
issn = "2287-979X",
publisher = "Korean Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Sequential chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type

AU - Lee, Jieun

AU - Kim, Chul Yong

AU - Park, Young Je

AU - Lee, Nam Kwon

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Background: The purpose of this report is to summarize our clinical experience of patients with stage I/II extranodal natural killer (NK)/T-cell lymphoma, nasal type, treated using sequential chemotherapy followed by radiotherapy (SCRT) or concurrent chemoradiotherapy (CCRT). Methods: Forty-three patients with stage I/II extranodal NK/T-cell lymphoma, nasal type, who received SCRT (16 patients) or CCRT (27 patients) were included in the present analysis. Results: The median follow-up time was 39 months (range, 4-171 months) for all patients, 77 months (range, 4-171 months) for the SCRT group, and 31 months (range, 6-132 months) for the CCRT group. There were no statistically significant differences between the SCRT and CCRT groups with regard to the 3-year progression-free survival (PFS) (56% vs. 41%, P=0.823) and 3-year overall survival (OS) (75% vs. 59%, P=0.670). Univariate analysis revealed that patients with tumors confined to the nasal cavity and patients achieved complete remission had better PFS and OS rates, regardless of the treatment sequence. Multivariate analysis revealed that patients with tumors confined to the nasal cavity and patients aged ≤60 years had better OS rates. Conclusion: The effect of SCRT and CCRT are similar in terms of survival outcomes of patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Our results show that tumors confined to the nasal cavity and an age ≤60 years were associated with a better prognosis.

AB - Background: The purpose of this report is to summarize our clinical experience of patients with stage I/II extranodal natural killer (NK)/T-cell lymphoma, nasal type, treated using sequential chemotherapy followed by radiotherapy (SCRT) or concurrent chemoradiotherapy (CCRT). Methods: Forty-three patients with stage I/II extranodal NK/T-cell lymphoma, nasal type, who received SCRT (16 patients) or CCRT (27 patients) were included in the present analysis. Results: The median follow-up time was 39 months (range, 4-171 months) for all patients, 77 months (range, 4-171 months) for the SCRT group, and 31 months (range, 6-132 months) for the CCRT group. There were no statistically significant differences between the SCRT and CCRT groups with regard to the 3-year progression-free survival (PFS) (56% vs. 41%, P=0.823) and 3-year overall survival (OS) (75% vs. 59%, P=0.670). Univariate analysis revealed that patients with tumors confined to the nasal cavity and patients achieved complete remission had better PFS and OS rates, regardless of the treatment sequence. Multivariate analysis revealed that patients with tumors confined to the nasal cavity and patients aged ≤60 years had better OS rates. Conclusion: The effect of SCRT and CCRT are similar in terms of survival outcomes of patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Our results show that tumors confined to the nasal cavity and an age ≤60 years were associated with a better prognosis.

KW - Chemoradiotherapy

KW - Extranodal NK/T-cell lymphoma

KW - Nasal type

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=84891084105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891084105&partnerID=8YFLogxK

U2 - 10.5045/br.2013.48.4.274

DO - 10.5045/br.2013.48.4.274

M3 - Article

AN - SCOPUS:84891084105

VL - 48

SP - 274

EP - 281

JO - Blood Research

JF - Blood Research

SN - 2287-979X

IS - 4

ER -